Inclusion Criteria

DISEASE CHARACTERISTICS: Diagnosis of resistant Hodgkin's disease Eligible subtypes:
Lymphocytic predominance Nodular sclerosing Mixed cellularity Lymphocyte depleted Not
otherwise specified Must meet 1 of the following conditions: Disease progression after at
least 1 course of prior therapy on each of 2 regimens comprising combination chemotherapy
or radiotherapy Less than a partial remission (PR) after at least 2 courses on each of 2
regimens Failure to achieve a complete remission (CR) after 6 courses of 1 or 2 regimens
Relapse less than 1 year off initial therapy OR Diagnosis of intermediate- or high-grade
non-Hodgkin's lymphoma (NHL) Eligible subtypes: Diffuse poorly differentiated lymphocytic
Diffuse mixed lymphocytic-histiocytic Nodular histiocytic Diffuse histiocytic Diffuse
undifferentiated Lymphoblastic Must meet 1 of the following conditions: Disease
progression after 1 course of prior therapy Failure to achieve a PR after 2 courses of
prior therapy Failure to achieve a CR after 6 courses of prior therapy OR Diagnosis of
low-grade NHL Eligible subtypes: Diffuse well-differentiated lymphocytic Nodular poorly
differentiated lymphocytic Nodular mixed lymphocytic-histiocytic Failure on second-line
therapy administered for progressive symptomatic disease or organ compromise Measurable
disease by physical exam, external imaging or scanning studies, or tumor markers No severe
symptomatic CNS disease of any etiology History of prior CNS tumor allowed if no signs or
symptoms at study entry Active CNS lymphoma (meningeal lymphomatosis) rendered
disease-free by conventional therapies allowed Epidural metastases or discrete parenchymal
brain lesions allowed if tumors can be encompassed in standard treatment fields Bilateral
marrow core biopsy free of tumor and showing at least 30% cellularity Prior marrow
involvement allowed if marrow is histologically normal at time of storage No significant
skin breakdown due to tumor or other disease A new classification scheme for adult
non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of "indolent" or
"aggressive" lymphoma will replace the former terminology of "low", "intermediate", or
"high" grade lymphoma. However, this protocol uses the former terminology.

PATIENT CHARACTERISTICS: Age: 15 to 65 Performance status: Karnofsky 70-100% OR ECOG 0-1
Life expectancy: At least 8 weeks without transplantation Hematopoietic: Granulocyte count
at least 1,500/mm3 Platelet count at least 150,000/mm3 Hepatic: Bilirubin no greater than
1.8 mg/dL SGOT and SGPT less than 2 times normal No high risk for veno-occlusive disease
of the liver Renal: No severe renal dysfunction unless due to tumor invasion Creatinine no
more than 1.5 mg/dL Creatinine at least 60 mL/min Cardiovascular: No severe cardiovascular
dysfunction unless due to tumor invasion No myocardial infarction within the past 6 months
No symptoms of major heart disease Ejection fraction at least 50% by MUGA scan Essential
hypertension controlled with medication allowed Pulmonary: No severe pulmonary dysfunction
unless due to tumor invasion DLCO at least 50% normal No symptomatic obstructive or
restrictive pulmonary disease Other: No insulin-dependent diabetes mellitus No
uncompensated major thyroid or adrenal dysfunction No active infection HTLV-III negative
(no AIDS-related complex)

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics At least 4 weeks since prior chemotherapy (at least 6 weeks since prior
nitrosoureas or mitomycin) Prior exposure to etoposide, cisplatin, or carmustine allowed
if cumulative dose of chloroethylnitrosourea (carmustine or lomustine) no greater than 400
mg/m2 Prior doxorubicin or daunorubicin dose of 450 mg/m2 or more allowed if LVEF at least
50% No concurrent chemotherapy Endocrine therapy: Concurrent corticosteroids for
hypercalcemia allowed Radiotherapy: See Disease Characteristics No prior whole-pelvic
radiotherapy Other prior radiotherapy allowed Surgery: Not specified Other: No concurrent
nitroglycerin preparations for angina pectoris No concurrent antiarrhythmic drugs for
major ventricular arrhythmias